This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011
GBI Research, the leading business intelligence provider, has released its latest research, "Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011", which provides insights into global pediatric vaccines market forecast until 2017. The report provides an in-depth analysis of six vaccines which include hepatitis A, hepatitis B, polio, rotavirus, Mumps, Measles and Rubella (MMR) and Diphtheria, Tetanus and Pertussis (DTaP). The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines Research and Development (R&D) pipeline.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
GBI Research analysis shows that the overall global pediatric vaccines market was valued at
$14 billion in 2010. The market is expected to witness a growth at a CAGR of 11.5% for the forecast period and will reach
$24.3 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development. The top pharmaceutical companies in the vaccines market are – GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & co. Inc and SP-MSD. Approximately 88% of the market is covered by the above six companies.
- Data and analysis on the global pediatric vaccines market